Skip to main content
. 2019 Sep 12;5(11):1574–1581. doi: 10.1001/jamaoncol.2019.2572

Figure 3. Disease-Free Survival (DFS) Rates According to Disease Risk and Regimen Used.

Figure 3.

Three-year DFS rates in patients with low-risk (A and B) and high-risk (C and D) disease treated with mFOLFOX6 (A and C) or CAPOX (B and D) regimens for 3 or 6 months. CAPOX indicates capecitabine plus oxaliplatin; HR, hazard ratio; mFOLFOX6, modified fluorouracil, l-leucovorin, and oxaliplatin; No., number of patients.